½ÃÀ庸°í¼­
»óǰÄÚµå
1595412

Æó·Å±¸±Õ °Ë»ç ½ÃÀå : ¹æ¹ý, ±â¼ú, Á¦Ç° À¯Çü, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Pneumococcal Testing Market by Method (Immunodiagnostics, Molecular Diagnostic, Point of Care Testing), Technology (Enzyme Linked Immunosorbent Assay, Immunofluorescence, Immunohistochemistry), Product Type, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 182 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Æó·Å±¸±Õ °Ë»ç ½ÃÀåÀº 2023³â¿¡ 16¾ï 6,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 18¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 8.99%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 30¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

Æó·Å±¸±Õ °Ë»ç¿¡´Â Æó·Å±¸±Õ¿¡ ÀÇÇÑ °¨¿°À» °ËÃâÇϱâ À§ÇÑ ´Ù¾çÇÑ Áø´Ü ¹æ¹ýÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. Æó·Å±¸±ÕÀº Àü ¼¼°èÀûÀ¸·Î ½É°¢ÇÑ ÀÌȯÀ²°ú »ç¸Á·ü, ƯÈ÷ À¯¾Æ ¹× ³ëÀÎÀÇ »ç¸Á·üÀ» À¯¹ßÇÏ´Â ¼¼±ÕÀÔ´Ï´Ù. Æó·Å±¸±Õ °Ë»çÀÇ Çʿ伺Àº ÀûÀýÇÑ Ä¡·á °áÁ¤À» µ½°í ÇÕº´ÁõÀ» ÁÙÀÌ°í °øÁß º¸°Ç °á°ú¸¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀ̵Ǵ Àû½Ã¿¡ Á¤È®ÇÑ °ËÃâÀÇ Çʿ伺¿¡¼­ ºñ·ÔµË´Ï´Ù. Æó·Å±¸±Õ °Ë»çÀÇ Ä¡·á´Â ÁÖ·Î ÀÓ»ó ÇöÀå, º´¿ø ¹× Áø´Ü ½ÇÇè½Ç¿¡¼­ ÀÌ·ç¾îÁö¸ç, ½Å¼ÓÇÑ Áø´ÜÀ» ÅëÇØ Ä¡·á ¼Óµµ¸¦ ³ôÀÌ°í ¹é½Å Àü·«¿¡ Á¤º¸¸¦ Á¦°øÇϰí Ç×»ýÁ¦ ³»¼º ±ÕÁÖÀÇ È®»êÀ» ¸ð´ÏÅ͸µÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÁÖ¿ä ÃÖÁ¾ »ç¿ëÀڷδ ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü, Á¤ºÎ ±â°ü, ¿¬±¸ ±â°ü µîÀÌ ÀÖ½À´Ï´Ù. ½ÃÀå ÀλçÀÌÆ®¿¡ µû¸£¸é Æó·Å ¹× ÆÐÇ÷Áõ ¹ß»ý·ü Áõ°¡, Áø´Ü ±â¼úÀÇ ±â¼ú ¹ßÀü, ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ Àü ¼¼°è Àνİú ÅõÀÚ Áõ°¡·Î ÀÎÇØ Å« ¼ºÀåÀ» °¡Á®¿Ô½À´Ï´Ù°í ÇÕ´Ï´Ù. ÇöÀå °Ë»ç ¹× ½Ç½Ã°£ PCRÀÇ ÃâÇöÀº ³ôÀº Á¤È®µµ¿Í ºü¸¥ °á°ú¸¦ Á¦°øÇÔÀ¸·Î½á ½ÃÀå È®ÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Áúº´ À¯º´·üÀÌ ³ô°í Áø´Ü ¼­ºñ½º°¡ ºÎÁ·ÇÑ ½ÅÈï ½ÃÀå¿¡´Â ºñÁî´Ï½º ±âȸ°¡ ³ÑÃijª°í ÀÖ½À´Ï´Ù. ºñ¿ë È¿À²ÀûÀÌ°í »ç¿ëÇϱ⠽¬¿î °Ë»ç ¼Ö·ç¼ÇÀ¸·Î ÀÌµé ½ÃÀå¿¡ ÁøÀÔÇÏ¸é ½ÃÀå Á¡À¯À²À» Å©°Ô È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª °í°¡ÀÇ Ã·´Ü Áø´Ü ±â¼ú ºñ¿ë, ±ÔÁ¦ ¹®Á¦, ¹Ì°³¹ß Áö¿ª¿¡¼­ÀÇ ÀÎ½Ä ºÎÁ· µîÀ¸·Î ÀÎÇØ ½ÃÀå ¼ºÀå¿¡´Â ÇѰ谡 ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±â¼úÀû À庮°ú ¼÷·ÃµÈ ÀηÂÀÇ Çʿ伺µµ °úÁ¦·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Çõ½Å ºÐ¾ß´Â ºñ¿ë È¿À²ÀûÀÌ°í ½Å¼ÓÇÏ¸ç ´ÙÁßÈ­µÈ Áø´Ü Å×½ºÆ®ÀÇ °³¹ß°ú °¨¿° ¿¹¹æÀ» À§ÇÑ ¹é½Å Ç÷ûÇü Ä¿¹ö¸®Áö Çâ»ó¿¡ ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ±â¾÷°ú Á¤ºÎ º¸°Ç ±â°ü°úÀÇ ¿¬±¸ ÀÚ±Ý Áö¿ø ¹× Á¤Ã¥ ¼ö¸³¿¡ ´ëÇÑ Çù·Â °ü°è´Â ½ÃÀå È®´ë¿¡ À¯¸ÁÇÕ´Ï´Ù. ½ÃÀå °æÀïÀº Ä¡¿­Çϸç, °¢ ±â¾÷Àº Á¦Ç° Â÷º°È­¸¦ ÅëÇØ ÁøÈ­ÇÏ´Â ÇコÄÉ¾î ¼ö¿ä¿¡ È¿°úÀûÀ¸·Î ´ëÀÀÇϱâ À§ÇØ Áö¼ÓÀûÀÎ ¿¬±¸¿Í ±â¼ú Çõ½ÅÀ» ¿ä±¸Çϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 16¾ï 6,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 18¾ï ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 30¾ï 3,000¸¸ ´Þ·¯
CAGR(%) 8.99%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Æó·Å±¸±Õ °Ë»ç ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Æó·Å±¸±Õ °Ë»ç ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ¸·Î º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Á¶±â Áø´Ü ¹× Á¶±â Ä¡·á °³¼±¿¡ µû¸¥ Æó·Å±¸±Õ °Ë»ç µµÀÔ È®´ë
    • Æó·Å±¸±Õ¼º ÁúȯÀÇ À¯º´·ü ±Þ»ó½Â
    • ¹é½Å ¹× ¾à¹° ºÐÀÚ °³¹ßÀ» À§ÇÑ ÁøÇà ÁßÀÎ ÀÓ»ó½ÃÇè
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Æó·Å±¸±Õ °Ë»ç¹ý °³¹ß¿¡ µû¸¥ °íºñ¿ë
  • ½ÃÀå ±âȸ
    • POC °Ë»çÀÇ Àα⠻ó½Â
    • ü¿ÜÁø´Ü(IVD) °Ë»ç ±â¼ú¿¡ ´ëÇÑ ¿¬±¸ °³¹ß ÅõÀÚ ¹× Áøº¸ Áõ°¡
  • ½ÃÀå °úÁ¦
    • Àü¹®°¡ ºÎÁ·

Portre's Five Forces: Æó·Å±¸±Õ °Ë»ç ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« µµ±¸

"Portre's Five Forces" ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÆÄ¾ÇÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Æó·Å±¸±Õ °Ë»ç ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Æó·Å±¸±Õ °Ë»ç ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀ̰í Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® Æó·Å±¸±Õ °Ë»ç ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

Æó·Å±¸±Õ °Ë»ç ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º Æó·Å±¸±Õ °Ë»ç ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Æó·Å±¸±Õ °Ë»ç ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Æó·Å±¸±Õ °Ë»ç ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

Æó·Å±¸±Õ °Ë»ç ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTLE ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå Æó·Å±¸±Õ °Ë»ç ½ÃÀå : ¹æ¹ýº°

  • ¸é¿ªÁø´Ü
  • ºÐÀÚÁø´Ü
  • POC(Point of Care) °Ë»ç

Á¦7Àå Æó·Å±¸±Õ °Ë»ç ½ÃÀå : ±â¼úº°

  • È¿¼Ò ¸é¿ªÃøÁ¤¹ý
  • ¸é¿ª Çü±¤¹ý
  • ¸é¿ªÁ¶Á÷È­ÇÐ
  • ÇÙ»ê ¹è¿­ ±â¹Ý ÁõÆø
  • ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ
  • ¿þ½ºÅÏ ºí·Ô Å×½ºÆ®

Á¦8Àå Æó·Å±¸±Õ °Ë»ç ½ÃÀå : Á¦Ç° À¯Çüº°

  • ¾Ö³Î¶óÀÌÀú
  • ¼Ò¸ðǰ

Á¦9Àå Æó·Å±¸±Õ °Ë»ç ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • º´¿ø ¹× Ŭ¸®´Ð

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ Æó·Å±¸±Õ °Ë»ç ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Æó·Å±¸±Õ °Ë»ç ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Æó·Å±¸±Õ °Ë»ç ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • Acon Labs Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux S.A.
  • Cepheid Inc.
  • F-Hoffmann la Roche Ltd.
  • Hologic, Inc.
  • Meridian Bioscience, Inc. by SD Biosensor
  • Novartis AG
  • Pfizer Inc.
  • Qiagen N.V.
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
LSH

The Pneumococcal Testing Market was valued at USD 1.66 billion in 2023, expected to reach USD 1.80 billion in 2024, and is projected to grow at a CAGR of 8.99%, to USD 3.03 billion by 2030.

Pneumococcal testing encompasses a range of diagnostic methods aimed at detecting infections caused by Streptococcus pneumoniae, a bacterium responsible for significant morbidity and mortality worldwide, particularly among young children and the elderly. The necessity of pneumococcal testing stems from the need for timely and accurate detection that aids in appropriate treatment decisions, thereby reducing complications and improving public health outcomes. Applications of pneumococcal testing are predominantly seen in clinical settings, hospitals, and diagnostic laboratories where rapid diagnosis can expedite treatment, inform vaccination strategies, and help monitor the spread of antibiotic-resistant strains. Key end-users include healthcare providers, government entities, and research institutions. Market insights reveal significant growth influenced by rising incidences of pneumonia and sepsis, technological advancements in diagnostic techniques, and increased awareness and investment in healthcare infrastructure globally. The advent of point-of-care testing and real-time PCR is driving market expansion by offering high accuracy and swift results. Opportunities abound in emerging markets where the prevalence of disease is high but diagnostic services are underserved. Penetrating these markets with cost-effective and easy-to-use testing solutions can markedly expand market share. However, market growth faces limitations such as the high cost of advanced diagnostic technologies, regulatory challenges, and a lack of awareness in underdeveloped regions. Technological barriers and the need for skilled personnel further pose challenges. Areas of innovation lie in the development of cost-effective, rapid, and multiplexed diagnostic tests, as well as enhanced vaccine serotype coverage to preempt infection. Collaboration between biotech companies and governmental health bodies for research funding and policy making is promising for market expansion. The nature of the market is highly competitive, encouraging continuous research and innovation for companies to differentiate their products and meet evolving healthcare demands effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 1.66 billion
Estimated Year [2024] USD 1.80 billion
Forecast Year [2030] USD 3.03 billion
CAGR (%) 8.99%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pneumococcal Testing Market

The Pneumococcal Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing adoption of pneumococcal testing with improvement in early diagnosis and treatment
    • Upsurge in the number of prevalence of pneumococcal disease
    • Ongoing clinical trials for development of vaccines and drug molecules
  • Market Restraints
    • High cost associated with the development of pneumococcal testing methods
  • Market Opportunities
    • Rising popularity for POC tests
    • Increasing R&D investments and advancements in testing technologies for in-vitro diagnostic (IVD)
  • Market Challenges
    • Dearth of professionals

Porter's Five Forces: A Strategic Tool for Navigating the Pneumococcal Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pneumococcal Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pneumococcal Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pneumococcal Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pneumococcal Testing Market

A detailed market share analysis in the Pneumococcal Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pneumococcal Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pneumococcal Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pneumococcal Testing Market

A strategic analysis of the Pneumococcal Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pneumococcal Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Acon Labs Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux S.A., Cepheid Inc., F-Hoffmann la Roche Ltd., Hologic, Inc., Meridian Bioscience, Inc. by SD Biosensor, Novartis AG, Pfizer Inc., Qiagen N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Pneumococcal Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Method, market is studied across Immunodiagnostics, Molecular Diagnostic, and Point of Care Testing.
  • Based on Technology, market is studied across Enzyme Linked Immunosorbent Assay, Immunofluorescence, Immunohistochemistry, Nucleic Acid Sequence Based Amplification, Polymerase Chain Reaction, and Western Blot Test.
  • Based on Product Type, market is studied across Analyzers and Consumables.
  • Based on End-User, market is studied across Ambulatory Surgical Centers and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of pneumococcal testing with improvement in early diagnosis and treatment
      • 5.1.1.2. Upsurge in the number of prevalence of pneumococcal disease
      • 5.1.1.3. Ongoing clinical trials for development of vaccines and drug molecules
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the development of pneumococcal testing methods
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising popularity for POC tests
      • 5.1.3.2. Increasing R&D investments and advancements in testing technologies for in-vitro diagnostic (IVD)
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pneumococcal Testing Market, by Method

  • 6.1. Introduction
  • 6.2. Immunodiagnostics
  • 6.3. Molecular Diagnostic
  • 6.4. Point of Care Testing

7. Pneumococcal Testing Market, by Technology

  • 7.1. Introduction
  • 7.2. Enzyme Linked Immunosorbent Assay
  • 7.3. Immunofluorescence
  • 7.4. Immunohistochemistry
  • 7.5. Nucleic Acid Sequence Based Amplification
  • 7.6. Polymerase Chain Reaction
  • 7.7. Western Blot Test

8. Pneumococcal Testing Market, by Product Type

  • 8.1. Introduction
  • 8.2. Analyzers
  • 8.3. Consumables

9. Pneumococcal Testing Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals & Clinics

10. Americas Pneumococcal Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pneumococcal Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pneumococcal Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Acon Labs Inc.
  • 3. Becton, Dickinson and Company
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux S.A.
  • 6. Cepheid Inc.
  • 7. F-Hoffmann la Roche Ltd.
  • 8. Hologic, Inc.
  • 9. Meridian Bioscience, Inc. by SD Biosensor
  • 10. Novartis AG
  • 11. Pfizer Inc.
  • 12. Qiagen N.V.
  • 13. Quest Diagnostics Incorporated
  • 14. Thermo Fisher Scientific Inc.
  • 15. Trinity Biotech PLC
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦